An oversubscribed $48 million Series B announced on July 16th offers a revealing look at where the neurovascular thrombectomy market may be heading.
Miami-based RapidPulse is developing a next-generation pulsed-aspiration catheter designed to remove blood clots during acute ischemic stroke. But the most notable part of the financing may be who helped lead it: Medtronic.
Rather than waiting for the technology to reach the market, Medtronic invested alongside co-leads TechWald Next and S3 Ventures. SBI Investment and the Florida Opportunity Fund also participated, joining existing investors Santé Ventures, Syntheon, Hatteras Venture Partners, and Epidarex Capital. The financing will support RapidPulse’s TURBO investigational device trial.
For an established neurovascular leader, the investment creates an early position in a technology that could become increasingly important to the stroke market.
Approximately 795,000 strokes occur annually in the U.S., with ischemic strokes representing roughly 87% of the total. Within that population, large-vessel occlusion (LVO) represents a critical target for mechanical thrombectomy because rapidly restoring blood flow can significantly influence patient outcomes.
The market surrounding these procedures continues to expand. Global neurovascular thrombectomy device sales reached approximately $830 million in 2025 and are projected to approach $1.14 billion by 2030, representing a mid-single-digit CAGR.
Medtronic, Stryker, and Penumbra anchor the competitive landscape. Penumbra has generated as much as $321 million in a single quarter from its aspiration catheter business, while Stryker’s $4.9 billion acquisition of Inari Medical in February 2025 strengthened its position in thrombectomy.
Medtronic is hardly entering unfamiliar territory. Its neurovascular portfolio already includes the Solitaire stent retriever and React aspiration catheter, supported by an established commercial presence in hospital neuro-interventional suites.
That context makes the Series B particularly interesting. Medtronic is not investing to gain exposure to stroke. It is securing an early position in a potential next-generation technology for a market where it already has products, customers, and distribution.
For Medtronic, there are several possible paths to the next generation of aspiration technology. It could develop another platform internally, acquire an emerging technology after clinical validation, or invest before that validation occurs.
The RapidPulse financing effectively creates that third path.
By participating now, Medtronic gains exposure while the TURBO data matures, rather than potentially competing for the asset later at a strategic acquisition premium.
The broader technology trend is equally important. The major neurovascular companies initially established their thrombectomy franchises around stent retrievers, but competition has increasingly shifted toward aspiration. Penumbra’s roadmap, Stryker’s broader thrombectomy strategy following Inari, and Medtronic’s investment here all reinforce that direction.
The next competitive question may increasingly be how quickly and cleanly a catheter can aspirate a clot.
The first development to watch is whether Medtronic’s investment eventually becomes something larger. A structured option or acquisition following a future U.S. clearance would fit the tuck-in-after-clearance pattern LSI has tracked across 2026.
Competitive responses also matter. With three major players anchoring the market, another move in aspiration from Stryker or Penumbra could intensify the race for next-generation technology.
Finally, market growth itself could surprise. Current forecasts imply a mid-single-digit CAGR, but broader LVO eligibility and adoption of faster aspiration technologies could push thrombectomy growth beyond consensus expectations.
Compass AI’s Prediction Agent (a Beta capability) makes three predictions: Medtronic acquires RapidPulse through a structured option or outright transaction within 30 months of U.S. clearance and before the company establishes an independent sales force; at least one of Stryker or Penumbra announces an aspiration technology deal or launch by mid-2027; and neurovascular thrombectomy exceeds its roughly 6% consensus CAGR, reaching double-digit growth during at least one of the next two years.
A $48 million financing is relatively small compared with the multibillion-dollar transactions occurring across thrombectomy. Strategically, however, it could prove far more consequential. Medtronic already has the neurovascular portfolio and commercial infrastructure. Now it also has an early position in a technology that could help shape where stroke intervention goes next.
Join the LSI Mailing List
Upcoming Events
17011 Beach Blvd, Suite 500
Huntington Beach, CA 92647
© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy | Your Privacy Choices | Delete my Data